NCT04398771View on ClinicalTrials.gov

To Evaluate Safety and Effectiveness of RovatitanTab.

UnknownOBSERVATIONAL
Enrollment

1,000

Participants

Timeline

Start Date

September 1, 2020

Primary Completion Date

January 31, 2022

Study Completion Date

May 31, 2022

Conditions
HypertensionHyperlipidemias
Interventions
DRUG

Rosuvastatin/Valsartan

Rovatitan QD for 12 weeks

Sponsors

Lead Sponsor

LG Chem
All Listed Sponsors
lead

LG Chem

INDUSTRY

NCT04398771 - To Evaluate Safety and Effectiveness of RovatitanTab. | Biotech Hunter | Biotech Hunter